Nilufer Pharma — neuroaffective therapeutics pipeline: NILU-001, a V1a antagonist for limerence; NILU-002, a PDE4 inhibitor for persistent POCD; NILU-003, an OXTR PAM.

NILU-001
V1a AntagonistLimerence
Preclinical
Phase I
Phase II
Phase III

4.5% of adults experience limerence at any given time — 2.9M+ patients in the U.S.